Table 3. Accuracy of D2-40 immunostaining for diagnosing malignant mesothelioma (MM).

Carcinoma	No. of studies	Cases	Controls	AUC	SEN [95% CI]	SPE [95% CI]	PLR [95% CI]	NLR [95% CI]	DOR [95% CI]
MM	22	862	1402	0.93	0.86 [0.84, 0.89]	0.77 [0.74, 0.79]	5.15 [3.30, 8.03]	0.18 [0.12, 0.27]	40.37 [19.97, 81.61]
Epithelioid MM	16	540	1020	0.96	0.92 [0.89, 0.94]	0.84 [0.82, 0.87]	6.56 [4.06, 10.58]	0.10 [0.06, 0.18]	85.38 [51.85, 140.60]
Biphasic MM	9	85	559	0.94	0.80 [0.70, 0.88]	0.90 [0.87, 0.92]	8.27 [4.22, 16.21]	0.24 [0.08, 0.70]	43.14 [15.53, 119.82]
Sarcomatoid MM	10	131	659	0.83	0.65 [0.56, 0.73]	0.84 [0.81, 0.87]	3.29 [1.75, 6.16]	0.52 [0.29, 0.92]	6.93 [2.05, 23.47]
Pleural MM	13	536	707	0.93	0.85 [0.82, 0.88]	0.81 [0.78, 0.84]	5.12 [2.94, 8.90]	0.19 [0.11, 0.33]	42.98 [15.21, 121.39]

AUC, Area under the curve; CI: Confidential interval; SEN, Sensitivity; SPE, Specificity; PLR: Positive likelihood ratio; NLR: Negative likelihood ratio; DOR: Diagnostic odds ratio.